DNA Damage Response in Brain Tumors: A Society for Neuro-Oncology Consensus Review on Mechanisms and Translational Efforts in Neuro-oncology

Overview

Journal Neuro Oncol

Publisher Oxford University Press

Specialties Neurology
Oncology

Date 2024 May 21

PMID 38770568

Authors

Rifaquat Rahman

Diana D Shi

Zachary J Reitman

Petra Hamerlik

John F de Groot

Daphne A Haas-Kogan

Alan D DAndrea

Erik P Sulman

Kirk Tanner

Nathalie Y R Agar

Jann N Sarkaria

Christopher L Tinkle

Ranjit S Bindra

Minesh P Mehta

Patrick Y Wen

Affiliations

Soon will be listed here.

Abstract

DNA damage response (DDR) mechanisms are critical to maintenance of overall genomic stability, and their dysfunction can contribute to oncogenesis. Significant advances in our understanding of DDR pathways have raised the possibility of developing therapies that exploit these processes. In this expert-driven consensus review, we examine mechanisms of response to DNA damage, progress in development of DDR inhibitors in IDH-wild-type glioblastoma and IDH-mutant gliomas, and other important considerations such as biomarker development, preclinical models, combination therapies, mechanisms of resistance and clinical trial design considerations.

Citing Articles

The Clinical and Molecular Landscape of Rosette-Forming Glioneuronal Tumors.

Yang Z, Zhang X Biomedicines. 2024; 12(10).

PMID: 39457636 PMC: 11505073. DOI: 10.3390/biomedicines12102325.

References

Lang F, Gilbert M, Puduvalli V, Weinberg J, Levin V, Yung W . Toward better early-phase brain tumor clinical trials: a reappraisal of current methods and proposals for future strategies. Neuro Oncol. 2002; 4(4):268-77. PMC: 1920662. DOI: 10.1093/neuonc/4.4.268. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Deland K, Starr B, Mercer J, Byemerwa J, Crabtree D, Williams N . Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models. J Clin Invest. 2020; 131(1). PMC: 7773366. DOI: 10.1172/JCI142158. View

Rahman R, Polley M, Alder L, Brastianos P, Anders C, Tawbi H . Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference. Lancet Oncol. 2023; 24(4):e161-e171. PMC: 10401610. DOI: 10.1016/S1470-2045(23)00005-0. View

Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y . Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 2020; 22(9):431-440. PMC: 7350150. DOI: 10.1016/j.neo.2020.06.009. View

Jackson C, Noorbakhsh S, Sundaram R, Kalathil A, Ganesa S, Jia L . Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors. Cancer Res. 2019; 79(17):4331-4338. PMC: 6810597. DOI: 10.1158/0008-5472.CAN-18-3394. View

Gorski D, Beckett M, Jaskowiak N, Calvin D, Mauceri H, Salloum R . Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999; 59(14):3374-8. View

Zenke F, Zimmermann A, Sirrenberg C, Dahmen H, Kirkin V, Pehl U . Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models. Mol Cancer Ther. 2020; 19(5):1091-1101. DOI: 10.1158/1535-7163.MCT-19-0734. View

Kwon M, Kim G, Kim R, Kim K, Kim S, Smith S . Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer. J Immunother Cancer. 2022; 10(7). PMC: 9258491. DOI: 10.1136/jitc-2022-005041. View

10.

Bakr A, Oing C, Kocher S, Borgmann K, Dornreiter I, Petersen C . Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation. Nucleic Acids Res. 2015; 43(6):3154-66. PMC: 4381069. DOI: 10.1093/nar/gkv160. View

11.

Wang Y, Wild A, Turcan S, Wu W, Sigel C, Klimstra D . Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas. Sci Adv. 2020; 6(17):eaaz3221. PMC: 7176409. DOI: 10.1126/sciadv.aaz3221. View

12.

Fulton B, Short S, James A, Nowicki S, McBain C, Jefferies S . PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clin Transl Radiat Oncol. 2018; 8:12-16. PMC: 5862667. DOI: 10.1016/j.ctro.2017.11.003. View

13.

Liu Y, Lu Y, Celiku O, Li A, Wu Q, Zhou Y . Targeting IDH1-Mutated Malignancies with NRF2 Blockade. J Natl Cancer Inst. 2019; 111(10):1033-1041. PMC: 6792082. DOI: 10.1093/jnci/djy230. View

14.

Murata R, Nishimura Y, Hiraoka M . An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys. 1997; 37(5):1107-13. DOI: 10.1016/s0360-3016(96)00628-1. View

15.

Ma J, Benitez J, Li J, Miki S, Ponte de Albuquerque C, Galatro T . Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair. Cancer Cell. 2019; 35(3):504-518.e7. PMC: 6424615. DOI: 10.1016/j.ccell.2019.01.020. View

16.

Golding S, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft X . Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther. 2009; 8(10):2894-902. PMC: 2761990. DOI: 10.1158/1535-7163.MCT-09-0519. View

17.

MacLeod G, Bozek D, Rajakulendran N, Monteiro V, Ahmadi M, Steinhart Z . Genome-Wide CRISPR-Cas9 Screens Expose Genetic Vulnerabilities and Mechanisms of Temozolomide Sensitivity in Glioblastoma Stem Cells. Cell Rep. 2019; 27(3):971-986.e9. DOI: 10.1016/j.celrep.2019.03.047. View

18.

Weterings E, Chen D . The endless tale of non-homologous end-joining. Cell Res. 2008; 18(1):114-24. DOI: 10.1038/cr.2008.3. View

19.

Rahman R, Trippa L, Lee E, Arrillaga-Romany I, Fell G, Touat M . Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. J Clin Oncol. 2023; 41(36):5524-5535. DOI: 10.1200/JCO.23.00493. View

20.

Walker M, Green S, Byar D, ALEXANDER Jr E, Batzdorf U, Brooks W . Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med. 1980; 303(23):1323-9. DOI: 10.1056/NEJM198012043032303. View